AbbVie Inc logo

AbbVie (ABBV) — Congressional Trading Activity

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

Members Trading

37

All-time in AbbVie

Buyers vs Sellers

0Buyers/1Sellers

Members buying vs selling · last 90 days

Trades (90d)

1

Disclosed in the last 90 days

Avg Member Return

+46.9%

Top performers, TTM

Stock Report
$15K - $50K
StockSaleRepublicanTexasSep 18, 2026Sep 14, 2026House
$15K - $50K
StockPurchaseRepublicanOklahomaJul 21, 2026Mar 27, 2026Senate
$1K - $15K
StockSaleDemocratNew JerseyJun 03, 2026May 05, 2026House
$1K - $15K
StockSaleDemocratTexasJan 15, 2026Dec 18, 2025House
$1K - $15K
StockSaleRepublicanLouisianaJan 13, 2026Dec 08, 2025House
$1K - $15K
StockPurchaseRepublicanLouisianaJan 13, 2026Oct 23, 2024House
$1K - $15K
StockSaleRepublicanLouisianaJan 13, 2026Jan 24, 2025House
$1K - $15K
StockPurchaseRepublicanLouisianaJan 13, 2026Apr 28, 2025House
$1K - $15K
StockSale (Partial)DemocratTexasDec 11, 2025Nov 13, 2025House
$1K - $15K
StockSaleRepublicanMichiganNov 21, 2025Oct 30, 2025House